[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343134-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343134-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","loxl2-induced-pear1-ser891-phosphorylation-suppresses-cd44-degradation-and-promotes-triple-negative-breast-cancer-metastasis","LOXL2-induced PEAR1 Ser891 phosphorylation suppresses CD44 degradation and promotes triple-negative breast cancer metastasis","","CD44 drives metastasis risk, recurrence, and drug resistance across cancers, and triple-negative breast cancer (TNBC) lacks effective targeted options. The study identifies platelet endothelial aggregation receptor 1 (PEAR1) as a CD44 chaperone that protects CD44 from endocytosis-mediated degradation and enhances CD44 intracellular domain (CD44-ICD) cleavage. Lysyl oxidase–like protein 2 (LOXL2) binds PEAR1, induces Ser891 phosphorylation independently of enzyme activity, and strengthens PEAR1–CD44 interactions, correlating with poor TNBC prognosis. Blocking LOXL2–PEAR1 interaction inhibits TNBC metastasis, supporting a therapeutic strategy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/loxl2-induced-pear1-ser891-phosphorylation-suppresses-cd44-degradation-and-promotes-triple-negative-breast-cancer-metastasis/343134/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/loxl2-induced-pear1-ser891-phosphorylation-suppresses-cd44-degradation-and-promotes-triple-negative-breast-cancer-metastasis/343134.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does PEAR1 play in CD44 stability and signaling?","Question",{"text":63,"@type":64},"PEAR1 acts as a CD44 chaperone, protecting CD44 from endocytosis-mediated degradation and promoting cleavage of the CD44 intracellular domain (CD44-ICD).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does LOXL2 influence PEAR1 and CD44?",{"text":68,"@type":64},"LOXL2 binds the PEAR1-EMI domain and facilitates PEAR1–CD44 interaction by inducing PEAR1 Ser891 phosphorylation independently of LOXL2 enzyme activity.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the prognostic significance of PEAR1 Ser891 phosphorylation in TNBC?",{"text":72,"@type":64},"PEAR1 protein levels and Ser891 phosphorylation increase in TNBC patients and correlate positively with LOXL2 and CD44 expression, but negatively with overall survival. Ser891 phosphorylation is identified as the best independent prognostic factor.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343134,1790206550,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","The Journal of Clinical Investigation RESEAR CH ARTICLE  \nLOXL2-induced PEAR1 Ser891 phosphorylation suppresses CD44 degradation and promotes triple-negative breast cancer metastasis  \nYingzhi Shen,1 Jie Yan,1 Lin Li,1 Huiyan Sun,1 Lin Zhang1, Guoming Li,1 Xinxia Wang,1 Ruoyan Liu,1 Xuefeng Wu,2 Baosan Han,3 Xueqing Sun,1 Junling Liu,1,4 and Xuemei Fan1  \n1Department of Biochemistry and Molecular Cell Biology, 2Shanghai Institute of Immunology, Department of Immunology and Microbiology, and 3Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 4Shanghai Synvida Biotechnology Co., Shanghai, China.  \nCD44 is associated with a high risk of metastasis, recurrence, and drug resistance in various cancers. Here we report that platelet endothelial aggregation receptor 1 (PEAR1) is a CD44 chaperone protein that protected CD44 from endocytosismediated degradation and enhances cleavage of the CD44 intracellular domain (CD44-ICD) . Furthermore, we found that lysyl oxidase–like protein 2 (LOXL2), an endogenous ligand of PEAR1, bound to the PEAR1-EMI domain and facilitated the interaction between PEAR1 and CD44 by inducing PEAR1 Ser891 phosphorylation in a manner that was independent of its enzyme activity. Levels of PEAR1 protein and PEAR1 phosphorylation at Ser891 were increased in patients with triplenegative breast cancer (TNBC), were positively correlated with expression of LOXL2 and CD44, and were negatively correlated with overall survival. The level of PEAR1 Ser891 phosphorylation was identified as the best independent prognostic factor in TNBC patients. The prognostic efficacy of the combination of PEAR1 phosphorylation at Ser891 and CD44 expression was superior to that of PEAR1 phosphorylation at Ser891 alone. Blocking the interaction between LOXL2 and PEAR1 with monoclonal antibodies significantly inhibited TNBC metastasis, representing a promising therapeutic strategy for TNBC.  \nIntroduction  \nBreast cancer is the most prevalent malignancy in women, and its incidence is increasing (1). Of particular concern is triple-negative breast cancer (TNBC), which is an exceptionally aggressive andresistant subtype, with high heterogeneity and an unfavorable prognosis (2). TNBC is distinguished by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression, which limits clinical treatment options (3). Thus, identification of novel therapeutic targets through comprehensive research on the molecular mechanisms underlying TNBC holds promise for the control ofTNBC progression and enhancement of treatment success. Notably, cancer stem cells (CSCs), a rare population of potent self-renewing but poorly differentiated cells, account for drug resistance, tumor recurrence, and metastasis in TNBC (4). Remarkably, CD44-positive with absent or low CD24 (CD44+CD24–/ lo) is the molecular marker profile most frequently used to identify TNBC stem cells (5, 6). Moreover, epithelial-mesenchymal transition (EMT) is enhanced inCSCs (7). Recently, the acquisition of both CSC properties and EMT phenotypes has garnered considerable attention as the pivotal driving force in cancer metastasis, and metastasis has emerged asthe primary cause of mortality inpatients with TNBC (8).  \nConflict of interest: The authors have declared that no conflict of interest exists. Copyright: © 2024, Shen et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.  \nSubmitted: November 8, 2023; Accepted: June 20, 2024; Published: August 15, 2024.  \nReference information: J Clin Invest. 2024;134(16):e177357.  \n[h](https://doi.org/10.1172/JCI177357)[ttps://doi.org/10.1172/JCI177357](https://doi.org/10.1172/JCI177357).  \nCD44 is highly expressed in advanced metastatic TNBC and acts as an important signal transduction control platform, contributing to tumorigenesis, progression, and metastas","cbCaiuxrGXXCYNP0","https://ap.wps.com/l/cbCaiuxrGXXCYNP0","pdf",11452177,17,"English","# Introduction\n# PEAR1, CD44, and LOXL2: molecular interactions and phosphorylation\n# Clinical relevance and prognostic value in TNBC\n# Therapeutic implication of blocking LOXL2–PEAR1","[{\"question\":\"What role does PEAR1 play in CD44 stability and signaling?\",\"answer\":\"PEAR1 acts as a CD44 chaperone, protecting CD44 from endocytosis-mediated degradation and promoting cleavage of the CD44 intracellular domain (CD44-ICD).\"},{\"question\":\"How does LOXL2 influence PEAR1 and CD44?\",\"answer\":\"LOXL2 binds the PEAR1-EMI domain and facilitates PEAR1–CD44 interaction by inducing PEAR1 Ser891 phosphorylation independently of LOXL2 enzyme activity.\"},{\"question\":\"What is the prognostic significance of PEAR1 Ser891 phosphorylation in TNBC?\",\"answer\":\"PEAR1 protein levels and Ser891 phosphorylation increase in TNBC patients and correlate positively with LOXL2 and CD44 expression, but negatively with overall survival. Ser891 phosphorylation is identified as the best independent prognostic factor.\"}]","LOXL2-induced PEAR1 Ser891 phosphorylation suppresses CD44 degradation and promotes triple-negative breast cancer metastasis | PDF",1790050045,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/84c3e43510c724cf957e82d196a215b6.webp",983,1315,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9a4493ef3765df72048261549ed2e6d7.webp",982,1314,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a8c4e529d8cdb7d902551d4da26741ee.webp",981,1312,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85f376ec93e4cdab93e6ea984000374d.webp",980,1311]